药食同源物质因兼具营养与药用价值，近年来备受关注。类黄酮成分作为药食同源物质中的关键活性成分，其通过调控肠道菌群干预代谢性疾病与神经退行性疾病的相关研究展现出良好应用前景。基于CiteSpace对近10年国内外相关文献进行可视化分析，系统梳理药食同源物质类黄酮成分（FMHFs）与肠道菌群的研究热点，归纳具有肠道菌群调节作用的常见FMHFs，阐明肠道菌群参与类黄酮代谢、显著提升其生物利用度与生物活性的作用机制；重点论述FMHFs通过促进有益菌增殖、抑制致病菌生长、调节肠道菌群代谢产物，进而从菌群结构与代谢物水平调控2型糖尿病、高脂血症、代谢相关脂肪性肝病（MAFLD）等代谢性疾病及阿尔茨海默病等神经退行性疾病发生发展的过程，并对其安全性进行评述，旨在为药食同源物质类黄酮新型制剂研发与临床应用提供理论依据和研究思路。

Due to their dual nutritional and medicinal values, substances with the same origin of food and medicine have attracted much attention in recent years. Flavonoids, as key active components of food-medicine homologous substances, have shown promising application prospects in the intervention of metabolic and neurodegenerative diseases by regulating the intestinal flora. Based on the visualization analysis of relevant domestic and foreign literature in the past 10 years using CiteSpace, this paper systematically reviews the research hotspots of food-medicine homologous flavonoids(FMHFs) and intestinal flora, summarizes the common FMHFs components with the ability to regulate intestinal flora, and clarifies the mechanism by which intestinal flora participates in the metabolism of flavonoids, significantly enhancing their bioavailability and biological activity. It focuses on discussing the process by which FMHFs regulate the occurrence and development of metabolic diseases such as type 2 diabetes, hyperlipidemia, and metabolic associated fatty liver disease(MAFLD), as well as neurodegenerative diseases such as Alzheimer's disease, by promoting the proliferation of beneficial bacteria, inhibiting the growth of pathogenic bacteria, and regulating the metabolic products of intestinal flora, from the perspectives of flora structure and metabolites. It also reviews their safety, aiming to provide theoretical basis and research ideas for the development of new formulations and clinical application of food-medicine homologous flavonoids.

R285.5；Q344.5